hu.MAP 3.0: Complex View
Human Protein Complex Map
Search for a protein
Complex: huMAP3_01523.1
Confidence: Extremely High
Proteins| Genename | Protein Name | Uniprot Annotation Score | Links |
|---|---|---|---|
| CDKN2D | Cyclin-dependent kinase 4 inhibitor D (p19-INK4d) | 5 | UniProt NCBI |
| CDKN2B | Cyclin-dependent kinase 4 inhibitor B (Multiple tumor suppressor 2) (MTS-2) (p14-INK4b) (p15-INK4b) (p15INK4B) | 5 | UniProt NCBI |
| CDK4 | Cyclin-dependent kinase 4 (EC 2.7.11.22) (Cell division protein kinase 4) (PSK-J3) | 5 | UniProt NCBI |
| CDK6 | Cyclin-dependent kinase 6 (EC 2.7.11.22) (Cell division protein kinase 6) (Serine/threonine-protein kinase PLSTIRE) | 5 | UniProt NCBI |
| CDKN2A | Tumor suppressor ARF (Alternative reading frame) (ARF) (Cyclin-dependent kinase inhibitor 2A) (p14ARF) | 5 | UniProt NCBI |
| CDKN2C | Cyclin-dependent kinase 4 inhibitor C (Cyclin-dependent kinase 6 inhibitor) (p18-INK4c) (p18-INK6) | 5 | UniProt NCBI |
Enrichments
| Term ID | Corrected Pval | Fraction Complex Coverage | Proteins | Term Name |
|---|---|---|---|---|
| REAC:R-HSA-2559585 | 6.93852633844e-12 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | Oncogene Induced Senescence |
| REAC:R-HSA-69236 | 4.00740415804e-11 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | G1 Phase |
| REAC:R-HSA-69231 | 4.00740415804e-11 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | Cyclin D associated events in G1 |
| WP:WP45 | 8.62488520905e-11 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | G1 to S cell cycle control |
| WP:WP179 | 1.81433372095e-09 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | Cell cycle |
| REAC:R-HSA-2559582 | 1.88408178672e-09 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | Senescence-Associated Secretory Phenotype (SASP) |
| REAC:R-HSA-2559580 | 3.10793467992e-09 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | Oxidative Stress Induced Senescence |
| KEGG:04110 | 5.34896053001e-09 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | Cell cycle |
| REAC:R-HSA-453279 | 1.56120199966e-08 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | Mitotic G1 phase and G1/S transition |
| GO:0004861 | 1.65724193228e-08 | 0.8 | CDKN2C CDKN2D CDKN2B CDKN2A | cyclin-dependent protein serine/threonine kinase inhibitor activity |
| REAC:R-HSA-2559583 | 3.77468168534e-08 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | Cellular Senescence |
| WP:WP2261 | 2.22775754131e-07 | 0.8 | CDKN2C CDKN2A CDKN2B CDK6 | Glioblastoma signaling pathways |
| WP:WP3998 | 3.0240871454e-07 | 0.8 | CDKN2C CDKN2A CDKN2B CDK6 | Prader Willi and Angelman syndrome |
| KEGG:04934 | 1.22968992878e-06 | 0.8 | CDKN2C CDKN2A CDKN2B CDK6 | Cushing syndrome |
| WP:WP2877 | 1.69660686196e-06 | 0.8 | CDKN2C CDKN2D CDKN2B CDKN2A | Vitamin D receptor pathway |
| GO:0030291 | 2.69021579342e-06 | 0.8 | CDKN2C CDKN2D CDKN2B CDKN2A | protein serine/threonine kinase inhibitor activity |
| HP:0006744 | 8.94078428367e-06 | 0.6 | CDKN2C CDKN2B CDKN2A | Adrenocortical carcinoma |
| GO:0000082 | 9.17514737719e-06 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | G1/S transition of mitotic cell cycle |
| REAC:R-HSA-69278 | 9.62433880318e-06 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | Cell Cycle, Mitotic |
| HP:0002888 | 1.07278390181e-05 | 0.6 | CDKN2C CDKN2B CDKN2A | Ependymoma |
| GO:0016538 | 1.46952249556e-05 | 0.8 | CDKN2C CDKN2D CDKN2B CDKN2A | cyclin-dependent protein serine/threonine kinase regulator activity |
| GO:0044843 | 1.71561180388e-05 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | cell cycle G1/S phase transition |
| HP:0100641 | 2.32711338381e-05 | 0.6 | CDKN2C CDKN2B CDKN2A | Neoplasm of the adrenal cortex |
| HP:0003118 | 2.65928487324e-05 | 0.6 | CDKN2C CDKN2B CDKN2A | Increased circulating cortisol level |
| REAC:R-HSA-1640170 | 2.71966699056e-05 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | Cell Cycle |
| REAC:R-HSA-9630750 | 4.55977246808e-05 | 0.4 | CDK6 CDKN2A | Evasion of Oncogene Induced Senescence Due to p16INK4A Defects |
| REAC:R-HSA-9630794 | 4.55977246808e-05 | 0.4 | CDK6 CDKN2A | Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 |
| REAC:R-HSA-9675132 | 4.55977246808e-05 | 0.4 | CDK6 CDKN2A | Diseases of cellular response to stress |
| REAC:R-HSA-9632693 | 4.55977246808e-05 | 0.4 | CDK6 CDKN2A | Evasion of Oxidative Stress Induced Senescence Due to p16INK4A Defects |
| REAC:R-HSA-9630747 | 4.55977246808e-05 | 0.4 | CDK6 CDKN2A | Diseases of Cellular Senescence |
| REAC:R-HSA-9632700 | 4.55977246808e-05 | 0.4 | CDK6 CDKN2A | Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 |
| REAC:R-HSA-2262752 | 4.74672993161e-05 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | Cellular responses to stress |
| REAC:R-HSA-8953897 | 4.98167253052e-05 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | Cellular responses to stimuli |
| GO:0000079 | 5.18179525184e-05 | 0.8 | CDKN2C CDKN2D CDKN2B CDKN2A | regulation of cyclin-dependent protein serine/threonine kinase activity |
| GO:0004860 | 5.96974946777e-05 | 0.8 | CDKN2C CDKN2D CDKN2B CDKN2A | protein kinase inhibitor activity |
| GO:1904029 | 6.84426164966e-05 | 0.8 | CDKN2C CDKN2D CDKN2B CDKN2A | regulation of cyclin-dependent protein kinase activity |
| GO:0019210 | 7.81144048072e-05 | 0.8 | CDKN2C CDKN2D CDKN2B CDKN2A | kinase inhibitor activity |
| HP:0002717 | 7.85415640073e-05 | 0.6 | CDKN2C CDKN2B CDKN2A | Adrenal overactivity |
| GO:1901990 | 8.91472005403e-05 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | regulation of mitotic cell cycle phase transition |
| HP:0100631 | 0.000129597601889 | 0.6 | CDKN2C CDKN2B CDKN2A | Neoplasm of the adrenal gland |
| HP:0009733 | 0.000186036891494 | 0.6 | CDKN2C CDKN2B CDKN2A | Glioma |
| HP:0002890 | 0.000241447043353 | 0.6 | CDKN2C CDKN2B CDKN2A | Thyroid carcinoma |
| HP:0011731 | 0.000241447043353 | 0.6 | CDKN2C CDKN2B CDKN2A | Abnormality of circulating cortisol level |
| HP:0012111 | 0.00025683213063 | 0.6 | CDKN2C CDKN2B CDKN2A | Abnormality of circulating glucocorticoid level |
| GO:0044772 | 0.000321329238954 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | mitotic cell cycle phase transition |
| GO:1901987 | 0.000335933015523 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | regulation of cell cycle phase transition |
| KEGG:04218 | 0.000411831232455 | 0.6 | CDKN2A CDKN2B CDK6 | Cellular senescence |
| GO:0008285 | 0.000626490498077 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | negative regulation of cell population proliferation |
| HP:0011761 | 0.000641107533884 | 0.4 | CDKN2C CDKN2B | Pituitary null cell adenoma |
| HP:0005605 | 0.000641107533884 | 0.4 | CDKN2C CDKN2B | Large cafe-au-lait macules with irregular margins |
| HP:0011759 | 0.000641107533884 | 0.4 | CDKN2C CDKN2B | Pituitary gonadotropic cell adenoma |
| HP:0012197 | 0.000641107533884 | 0.4 | CDKN2C CDKN2B | Insulinoma |
| HP:0011762 | 0.000641107533884 | 0.4 | CDKN2C CDKN2B | Pituitary thyrotropic cell adenoma |
| HP:0100522 | 0.000641107533884 | 0.4 | CDKN2C CDKN2B | Thymoma |
| HP:0040306 | 0.000641107533884 | 0.4 | CDKN2C CDKN2B | Decreased male libido |
| GO:0007346 | 0.000651348502741 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | regulation of mitotic cell cycle |
| HP:0500167 | 0.000961529670085 | 0.4 | CDKN2C CDKN2B | Hypergastrinemia |
| HP:0500166 | 0.000961529670085 | 0.4 | CDKN2C CDKN2B | Abnormal circulating gastrin concentration |
| HP:0006780 | 0.000961529670085 | 0.4 | CDKN2C CDKN2B | Parathyroid carcinoma |
| HP:0030404 | 0.000961529670085 | 0.4 | CDKN2C CDKN2B | Glucagonoma |
| HP:0006723 | 0.000961529670085 | 0.4 | CDKN2C CDKN2B | Intestinal carcinoid |
| KEGG:05203 | 0.000966347133386 | 0.6 | CDKN2A CDKN2B CDK6 | Viral carcinogenesis |
| GO:0044770 | 0.000969015756776 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | cell cycle phase transition |
| HP:0002894 | 0.00103313648748 | 0.6 | CDKN2C CDKN2B CDKN2A | Neoplasm of the pancreas |
| HP:0100031 | 0.00107327796683 | 0.6 | CDKN2C CDKN2B CDKN2A | Neoplasm of the thyroid gland |
| HP:0030063 | 0.00111444304982 | 0.6 | CDKN2C CDKN2B CDKN2A | Neuroepithelial neoplasm |
| HP:0030060 | 0.00115664447875 | 0.6 | CDKN2C CDKN2B CDKN2A | Nervous tissue neoplasm |
| HP:0030061 | 0.00115664447875 | 0.6 | CDKN2C CDKN2B CDKN2A | Neuroectodermal neoplasm |
| KEGG:05166 | 0.0011654087209 | 0.6 | CDKN2C CDKN2B CDKN2A | Human T-cell leukemia virus 1 infection |
| HP:0100829 | 0.001345957274 | 0.4 | CDKN2C CDKN2B | Galactorrhea |
| HP:0100521 | 0.001345957274 | 0.4 | CDKN2C CDKN2B | Neoplasm of the thymus |
| HP:0031094 | 0.001345957274 | 0.4 | CDKN2C CDKN2B | Abnormal breast physiology |
| HP:0006767 | 0.001345957274 | 0.4 | CDKN2C CDKN2B | Pituitary prolactin cell adenoma |
| HP:0040085 | 0.001345957274 | 0.4 | CDKN2C CDKN2B | Abnormal circulating aldosterone |
| GO:2000045 | 0.00135049906212 | 0.8 | CDKN2C CDKN2D CDKN2B CDKN2A | regulation of G1/S transition of mitotic cell cycle |
| HP:0100836 | 0.00143232921071 | 0.6 | CDKN2C CDKN2B CDKN2A | Malignant neoplasm of the central nervous system |
| HP:0031071 | 0.00158519273527 | 0.6 | CDKN2C CDKN2B CDKN2A | Abnormal endocrine morphology |
| HP:0011732 | 0.00158519273527 | 0.6 | CDKN2C CDKN2B CDKN2A | Abnormal adrenal morphology |
| HP:0001579 | 0.00179436403841 | 0.4 | CDKN2C CDKN2B | Primary hypercortisolism |
| HP:0008261 | 0.00179436403841 | 0.4 | CDKN2C CDKN2B | Pancreatic islet cell adenoma |
| HP:0002039 | 0.00204495106592 | 0.6 | CDKN2C CDKN2B CDKN2A | Anorexia |
| HP:0011733 | 0.00230478017415 | 0.6 | CDKN2C CDKN2B CDKN2A | Abnormality of adrenal physiology |
| HP:0032044 | 0.00230672366147 | 0.4 | CDKN2C CDKN2B | Decreased vigilance |
| HP:0008208 | 0.00230672366147 | 0.4 | CDKN2C CDKN2B | Parathyroid hyperplasia |
| HP:0007449 | 0.00230672366147 | 0.4 | CDKN2C CDKN2B | Confetti-like hypopigmented macules |
| HP:0002044 | 0.00230672366147 | 0.4 | CDKN2C CDKN2B | Zollinger-Ellison syndrome |
| HP:0046504 | 0.00230672366147 | 0.4 | CDKN2C CDKN2B | Decreased libido |
| HP:0030445 | 0.00230672366147 | 0.4 | CDKN2C CDKN2B | Pulmonary carcinoid tumor |
| HP:0000849 | 0.00230672366147 | 0.4 | CDKN2C CDKN2B | Adrenocortical abnormality |
| GO:1902806 | 0.00250487001462 | 0.8 | CDKN2C CDKN2D CDKN2B CDKN2A | regulation of cell cycle G1/S phase transition |
| WP:WP4204 | 0.00254884296025 | 0.4 | CDK6 CDKN2A | Tumor suppressor activity of SMARCB1 |
| HP:0002588 | 0.00288300984678 | 0.4 | CDKN2C CDKN2B | Duodenal ulcer |
| HP:0008200 | 0.00288300984678 | 0.4 | CDKN2C CDKN2B | Primary hyperparathyroidism |
| HP:0012232 | 0.00288300984678 | 0.4 | CDKN2C CDKN2B | Shortened QT interval |
| HP:0030448 | 0.00296757123606 | 0.6 | CDKN2C CDKN2B CDKN2A | Soft tissue sarcoma |
| HP:0000845 | 0.0035231963033 | 0.4 | CDKN2C CDKN2B | Elevated circulating growth hormone concentration |
| GO:0010564 | 0.00381086825308 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | regulation of cell cycle process |
| HP:0008291 | 0.00422725674544 | 0.4 | CDKN2C CDKN2B | Pituitary corticotropic cell adenoma |
| HP:0003144 | 0.00422725674544 | 0.4 | CDKN2C CDKN2B | Increased serum serotonin |
| HP:0030405 | 0.00422725674544 | 0.4 | CDKN2C CDKN2B | Pancreatic endocrine tumor |
| GO:0019887 | 0.00480818953079 | 0.8 | CDKN2C CDKN2D CDKN2B CDKN2A | protein kinase regulator activity |
| HP:0100570 | 0.00499516489297 | 0.4 | CDKN2C CDKN2B | Carcinoid tumor |
| HP:0011151 | 0.00499516489297 | 0.4 | CDKN2C CDKN2B | Atypical absence status epilepticus |
| HP:0100568 | 0.00509344150575 | 0.6 | CDKN2C CDKN2B CDKN2A | Neoplasm of the endocrine system |
| GO:1903047 | 0.00564284704723 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | mitotic cell cycle process |
| HP:0100705 | 0.00581076944422 | 0.6 | CDKN2C CDKN2B CDKN2A | Abnormal glial cell morphology |
| HP:0032860 | 0.00582689447108 | 0.4 | CDKN2C CDKN2B | Generalized non-convulsive status epilepticus without coma |
| HP:0012091 | 0.00632439614707 | 0.6 | CDKN2C CDKN2B CDKN2A | Abnormality of pancreas physiology |
| HP:0011760 | 0.00672241921037 | 0.4 | CDKN2C CDKN2B | Pituitary growth hormone cell adenoma |
| HP:0100733 | 0.00672241921037 | 0.4 | CDKN2C CDKN2B | Neoplasm of the parathyroid gland |
| HP:0011407 | 0.00672241921037 | 0.4 | CDKN2C CDKN2B | Proportionate tall stature |
| HP:0011772 | 0.00744020362032 | 0.6 | CDKN2C CDKN2B CDKN2A | Abnormal thyroid morphology |
| GO:0071900 | 0.0074486057851 | 0.8 | CDKN2C CDKN2D CDKN2B CDKN2A | regulation of protein serine/threonine kinase activity |
| HP:0002248 | 0.00768171284681 | 0.4 | CDKN2C CDKN2B | Hematemesis |
| HP:0032671 | 0.00768171284681 | 0.4 | CDKN2C CDKN2B | Non-convulsive status epilepticus without coma |
| HP:0100242 | 0.0080439694067 | 0.6 | CDKN2C CDKN2B CDKN2A | Sarcoma |
| HP:0100006 | 0.0085175071765 | 0.6 | CDKN2C CDKN2B CDKN2A | Neoplasm of the central nervous system |
| KEGG:05218 | 0.00852542753416 | 0.4 | CDK6 CDKN2A | Melanoma |
| HP:0000169 | 0.00870474912182 | 0.4 | CDKN2C CDKN2B | Gingival fibromatosis |
| GO:0019207 | 0.00893796193013 | 0.8 | CDKN2C CDKN2D CDKN2B CDKN2A | kinase regulator activity |
| KEGG:04115 | 0.00908648748607 | 0.4 | CDK6 CDKN2A | p53 signaling pathway |
| HP:0002249 | 0.00979150178217 | 0.4 | CDKN2C CDKN2B | Melena |
| HP:0011766 | 0.00979150178217 | 0.4 | CDKN2C CDKN2B | Abnormal parathyroid morphology |
| HP:0032367 | 0.00979150178217 | 0.4 | CDKN2C CDKN2B | Abnormal growth hormone level |
| GO:0042326 | 0.0100477300178 | 0.8 | CDKN2C CDKN2D CDKN2B CDKN2A | negative regulation of phosphorylation |
| KEGG:05223 | 0.0102617382696 | 0.4 | CDK6 CDKN2A | Non-small cell lung cancer |
| KEGG:05214 | 0.0102617382696 | 0.4 | CDK6 CDKN2A | Glioma |
| WP:WP4685 | 0.010328593539 | 0.4 | CDK6 CDKN2A | Melanoma |
| HP:0000834 | 0.0104114042184 | 0.6 | CDKN2C CDKN2B CDKN2A | Abnormality of the adrenal glands |
| HP:0031475 | 0.0109419445801 | 0.4 | CDKN2C CDKN2B | Status epilepticus without prominent motor symptoms |
| HP:0000847 | 0.0109419445801 | 0.4 | CDKN2C CDKN2B | Abnormality of renin-angiotensin system |
| HP:0004375 | 0.01116370646 | 0.6 | CDKN2C CDKN2B CDKN2A | Neoplasm of the nervous system |
| KEGG:05212 | 0.0115077320087 | 0.4 | CDK6 CDKN2A | Pancreatic cancer |
| HP:0003528 | 0.0121560512731 | 0.4 | CDKN2C CDKN2B | Elevated circulating calcitonin concentration |
| HP:0034902 | 0.0121560512731 | 0.4 | CDKN2C CDKN2B | Abnormal circulating calcitonin concentration |
| KEGG:05220 | 0.012157220678 | 0.4 | CDK6 CDKN2A | Chronic myeloid leukemia |
| WP:WP4255 | 0.0128896073912 | 0.4 | CDK6 CDKN2A | Non small cell lung cancer |
| KEGG:05200 | 0.0130900202546 | 0.6 | CDKN2A CDKN2B CDK6 | Pathways in cancer |
| HP:0000843 | 0.0134337956242 | 0.4 | CDKN2C CDKN2B | Hyperparathyroidism |
| WP:WP4674 | 0.0140730862084 | 0.4 | CDK6 CDKN2A | Head and neck squamous cell carcinoma |
| GO:0000278 | 0.0146199281894 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | mitotic cell cycle |
| KEGG:01522 | 0.0149314441262 | 0.4 | CDKN2C CDKN2A | Endocrine resistance |
| KEGG:05222 | 0.0164241113683 | 0.4 | CDKN2B CDK6 | Small cell lung cancer |
| WP:WP4263 | 0.0188521857166 | 0.4 | CDK6 CDKN2A | Pancreatic adenocarcinoma pathway |
| HP:0020073 | 0.0191806250585 | 0.4 | CDKN2C CDKN2B | Hypopigmented macule |
| HP:0040202 | 0.0207498058008 | 0.6 | CDKN2C CDKN2B CDKN2A | Abnormal consumption behavior |
| HP:0002666 | 0.0207761643339 | 0.4 | CDKN2C CDKN2B | Pheochromocytoma |
| HP:0006476 | 0.0224351839587 | 0.4 | CDKN2C CDKN2B | Abnormality of the pancreatic islet cells |
| WP:WP4658 | 0.0227605362571 | 0.4 | CDKN2B CDK6 | Small cell lung cancer |
| GO:0045936 | 0.0230362545099 | 0.8 | CDKN2C CDKN2D CDKN2B CDKN2A | negative regulation of phosphate metabolic process |
| GO:0010563 | 0.0233977310013 | 0.8 | CDKN2C CDKN2D CDKN2B CDKN2A | negative regulation of phosphorus metabolic process |
| HP:0001012 | 0.0241576577336 | 0.4 | CDKN2C CDKN2B | Multiple lipomas |
| HP:0012093 | 0.0241576577336 | 0.4 | CDKN2C CDKN2B | Abnormality of endocrine pancreas physiology |
| GO:0004857 | 0.0245076542493 | 0.8 | CDKN2C CDKN2D CDKN2B CDKN2A | enzyme inhibitor activity |
| GO:0051726 | 0.0271469239089 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | regulation of cell cycle |
| KEGG:04068 | 0.028330266578 | 0.4 | CDKN2D CDKN2B | FoxO signaling pathway |
| HP:0010615 | 0.0297055420477 | 0.4 | CDKN2C CDKN2B | Angiofibromas |
| HP:0100530 | 0.0337209222644 | 0.4 | CDKN2C CDKN2B | Abnormal circulating calcium-phosphate regulating hormone concentration |
| HP:0031845 | 0.0337209222644 | 0.4 | CDKN2C CDKN2B | Abnormal libido |
| HP:0100634 | 0.0358235710582 | 0.4 | CDKN2C CDKN2B | Neuroendocrine neoplasm |
| HP:0010929 | 0.0384213686055 | 0.6 | CDKN2C CDKN2B CDKN2A | Abnormal blood cation concentration |
| GO:0006468 | 0.0389285508109 | 1.0 | CDKN2C CDKN2D CDKN2A CDKN2B CDK6 | protein phosphorylation |
| HP:0011747 | 0.0392998178372 | 0.6 | CDKN2C CDKN2B CDKN2A | Abnormality of the anterior pituitary |
| HP:0001732 | 0.0401914297306 | 0.6 | CDKN2C CDKN2B CDKN2A | Abnormality of the pancreas |
| HP:0004398 | 0.0402186552091 | 0.4 | CDKN2C CDKN2B | Peptic ulcer |
| HP:0034930 | 0.0410962983883 | 0.6 | CDKN2C CDKN2B CDKN2A | Digestive system neoplasm |
| HP:0007378 | 0.0410962983883 | 0.6 | CDKN2C CDKN2B CDKN2A | Neoplasm of the gastrointestinal tract |
| HP:0002027 | 0.044850219801 | 0.6 | CDKN2C CDKN2B CDKN2A | Abdominal pain |
| HP:0025085 | 0.0448666137641 | 0.4 | CDKN2C CDKN2B | Bloody diarrhea |
| HP:0003111 | 0.0453347787474 | 0.6 | CDKN2C CDKN2B CDKN2A | Abnormal blood ion concentration |
| HP:0012503 | 0.0453347787474 | 0.6 | CDKN2C CDKN2B CDKN2A | Abnormal pituitary gland morphology |
| KEGG:05206 | 0.0484667159694 | 0.4 | CDK6 CDKN2A | MicroRNAs in cancer |
| CORUM:1642 | 0.0498708842806 | 0.2 | CDKN2A | p16-cyclin D2-CDK4 complex |
| CORUM:3088 | 0.0498708842806 | 0.2 | CDK6 | CCND2-CDK6 complex |
| CORUM:3089 | 0.0498708842806 | 0.2 | CDK6 | CCND3-CDK6 complex |
| CORUM:5100 | 0.0498708842806 | 0.2 | CDK6 | CyclinD3-CDK4-CDK6 complex |
Edges
| Protein 1 | Protein 2 | Score | ProteomeHD | Evidence |
|---|---|---|---|---|
| CDK4 | CDKN2C | 1.0 | 0.138483660131 | bioplex3_HEK293 bioplex () bioplex_WMM bioplex3_WMM bioplex3_HCT116 |
| CDK6 | CDKN2C | 1.0 | 0.120941176471 | bioplex3_HEK293 bioplex () bioplex_WMM bioplex3_WMM bioplex3_HCT116 |
| CDK4 | CDKN2A | 0.998 | 0.182 | hein_WMM bioplex3_HEK293 bioplex () bioplex_WMM bioplex3_WMM youn_WMM hein () gupta_WMM |
| CDKN2D | CDK6 | 0.997 | bioplex3_HEK293 bioplex () bioplex_WMM bioplex3_WMM bioplex3_HCT116 | |
| CDKN2B | CDK4 | 0.996 | hein_WMM bioplex3_HEK293 bioplex () bioplex_WMM bioplex3_WMM hein () bioplex3_HCT116 | |
| CDKN2D | CDK4 | 0.995 | bioplex3_HEK293 bioplex () bioplex_WMM bioplex3_WMM bioplex3_HCT116 | |
| CDKN2B | CDK6 | 0.994 | bioplex3_HEK293 bioplex () bioplex_WMM bioplex3_WMM bioplex3_HCT116 | |
| CDK4 | CDK6 | 0.981 | 0.084 | bioplex3_HEK293 bioplex () bioplex_WMM bioplex3_WMM bioplex3_HCT116 |
| CDK6 | CDKN2A | 0.979 | 0.08 | bioplex3_HEK293 bioplex () bioplex_WMM bioplex3_WMM |
| CDKN2D | CDKN2B | 0.96 | bioplex_WMM bioplex3_WMM WMM_only | |
| CDKN2D | CDKN2C | 0.95 | bioplex_WMM bioplex3_WMM WMM_only | |
| CDKN2A | CDKN2C | 0.924 | 0.084 | bioplex_WMM bioplex3_WMM WMM_only |
| CDKN2B | CDKN2C | 0.911 | bioplex_WMM bioplex3_WMM WMM_only | |
| CDKN2B | CDKN2A | 0.866 | hein_WMM bioplex_WMM bioplex3_WMM WMM_only | |
| CDKN2D | CDKN2A | 0.295 | bioplex_WMM bioplex3_WMM WMM_only |
Related Complexes